Restart Life Sciences Announces Closing First Tranche of Financing

Restart Life Sciences (OTC Pink: NMLSF) closed the first tranche of a non-brokered private placement on December 5, 2025, raising CDN$500,000 by issuing 5,000,000 units at CDN$0.10 per unit.

Rhea-AI Summary

Restart Life Sciences (OTC Pink: NMLSF) closed the first tranche of a non-brokered private placement on December 5, 2025, raising CDN$500,000 by issuing 5,000,000 units at CDN$0.10 per unit. Each unit includes one common share and one one-year warrant exercisable at CAD$0.10. The company paid CAD$16,800 in cash finder's fees and issued 60,000 non-transferable finder warrants exercisable at CAD$0.10 for one year. Proceeds are intended for health food trials, potential acquisitions, and general working capital. All securities are subject to a hold period ending April 6, 2026.

Positive

• Raised CDN$500,000 in first tranche financing
• Issued 5,000,000 units at CAD$0.10 each
• Proceeds allocated to health food trials and acquisitions

Negative

• Potential dilution of 5,060,000 additional shares via warrants
• Paid CAD$16,800 cash in finder's fees
• Warrants exercisable at low strike of CAD$0.10 for one year

Argus Dec 8 session

+27.06% close to close Open Argus

Details

News Market Reaction – NMLSF

On Dec 8, the first trading day after this news, NMLSF closed 27.06% above the previous close.

Data tracked by StockTitan Argus for the Dec 8 session.

Key Figures

Gross proceeds: CDN$500,000 Units issued: 5,000,000 units Unit price: CDN$0.10 +5 more

Gross proceeds

CDN$500,000

First tranche non-brokered private placement

Units issued

5,000,000 units

Private placement at CDN$0.10 per unit

Unit price

CDN$0.10

Pricing of private placement units

Finder fees (cash)

CAD$16,800

Cash finder’s fees paid for placement

Finder warrants

60,000 warrants

Non-transferable finder warrants issued

Warrant exercise price

CAD$0.10

Exercise price for one-year warrants and finder warrants

Warrant term

1 year

Exercise period for placement and finder warrants

Hold period expiry

April 6, 2026

Hold period of four months and one day on securities

Historical Context

1 past event · Latest: Dec 05

1 event

1. Dec 05

   Financing tranche close

   24h Move

   +27.1%

   Closed first tranche of non-brokered private placement raising CDN$500,000.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

private placement, warrant

2 terms

private placement financial

"the Company has closed the first tranche of its non-brokered private placement"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

warrant financial

"one transferable common share purchase warrant (each, a "Warrant")"

A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") announces that further to its news release dated November 12, 2025, the Company has closed the first tranche of its non-brokered private placement for total gross proceeds of CDN$500,000 (the "Placement").

Pursuant to the Placement, the Company has allotted and issued 5,000,000 units (the "Units") at a price of CDN$0.10 per Unit. Each Unit consists of one common share and one transferable common share purchase warrant (each, a "Warrant"). Each Warrant entitles the holder to purchase one additional common share for a period of one (1) year at a price of CAD $0.10 per common share.

In connection with the Placement, the Company paid cash finder's fees totaling CAD $16,800 and issued 60,000 non-transferable finder warrants (each, a "Finder Warrant") to certain eligible arm's-length finders who introduced subscribers to the Placement. Each Finder Warrant entitles the holder to purchase one common share for a period of one (1) year at a price of CAD $0.10 per common share.

The Company intends to use the proceeds from the Offering towards health food trials, potential acquisitions, and general working capital. All securities issued under the Placement are subject to a hold period of four months and one day expiring on April 6, 2026.

About Restart Life Sciences Corp.
Restart Life Sciences Corp. is a Canadian-based life sciences company listed on the CSE. For more information about Restart Life, please visit the Company's website at www.restartlife.co.

On behalf of the Board of Directors
Steve Loutskou
Chief Executive Officer, Restart Life Sciences Corp.
Tel: +1 (778) 819-0244
Email: hello@restartlife.co

Forward-Looking Statements
This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Restart Life Sciences' actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277058

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Restart Life Sciences (NMLSF) announce on December 5, 2025?

Restart Life closed a CDN$500,000 first tranche private placement issuing 5,000,000 units at CAD$0.10 per unit.

How are the units structured in Restart Life's NMLSF financing?

Each unit contains one common share plus one transferable warrant exercisable at CAD$0.10 for one year.

What is the hold period and expiry date for securities from Restart Life's placement (NMLSF)?

All securities are subject to a four-month-and-one-day hold period ending on April 6, 2026.

How will Restart Life (NMLSF) use the proceeds from the CDN$500,000 placement?

The company intends to use proceeds for health food trials, potential acquisitions, and general working capital.

What finder compensation did Restart Life pay in the NMLSF placement?

The company paid CAD$16,800 in cash finder's fees and issued 60,000 non-transferable finder warrants.

How much potential dilution could Restart Life (NMLSF) face from this financing?

Warrants issued could convert to 5,060,000 additional shares (5,000,000 unit warrants plus 60,000 finder warrants) at CAD$0.10 within one year.